Acuta Capital Partners’s Gossamer Bio GOSS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-284,500
Closed -$3.41M 40
2022
Q3
$3.41M Buy
284,500
+252,500
+789% +$3.13M 1.47% 20
2022
Q2
$268K Buy
+32,000
New +$248K 0.15% 38
2022
Q1
Sell
-119,843
Closed -$1.35M 43
2021
Q4
$1.35M Sell
119,843
-95,157
-44% -$1.13M 0.57% 32
2021
Q3
$2.7M Buy
+215,000
New +$1.98M 0.95% 28
2019
Q2
Sell
-60,000
Closed -$1.3M 36
2019
Q1
$1.3M Buy
+60,000
New +$1.25M 0.62% 28

Other funds holding GOSS

Acuta Capital Partners's GOSS Position: Q4 2022 in Review

Acuta Capital Partners sold out of Gossamer Bio (GOSS) in Q4 2022, closing a stake of 284,500 shares — an estimated $3.41M sold.

Acuta Capital Partners first reported a position in GOSS in Q1 2019 and held it in 5 quarters. The position peaked at $3.41M in Q3 2022. 120 funds tracked by Wall St. Rank hold GOSS as of Q4 2022.

  • Acuta Capital Partners reported no remaining Gossamer Bio position as of Q4 2022 after selling out during the quarter.
  • Acuta Capital Partners sold 284,500 Gossamer Bio shares in Q4 2022, an estimated $3.41M.
  • Acuta Capital Partners first reported a position in Gossamer Bio in Q1 2019 and held it in 5 quarters.
  • Acuta Capital Partners's Gossamer Bio position peaked at $3.41M in Q3 2022.
  • 120 funds tracked by Wall St. Rank held Gossamer Bio as of Q4 2022.

Based on Acuta Capital Partners's 13F filing for Q4 2022, filed 14 Feb 2023.